Nanoparticles-based anti-aging treatment of Alzheimer's disease

Drug Deliv. 2022 Dec;29(1):2100-2116. doi: 10.1080/10717544.2022.2094501.

Abstract

Age is the strongest risk factor for Alzheimer's disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic efficacy. This review discusses the relationship between aging and AD and the application and prospect of anti-aging strategies and nanoparticle-based therapeutics in treating AD.

Keywords: AD; BBB; anti-aging; anti-inflammation; nanoparticles; senescent cells.

Publication types

  • Review

MeSH terms

  • Aging
  • Alzheimer Disease* / drug therapy
  • Biological Transport
  • Blood-Brain Barrier
  • Humans
  • Nanoparticles*

Grants and funding

This research was funded by Science and Technology Support Projects in Biomedicine Field of Shanghai Science and Technology Commission, grant number #19441907500, Shanghai Natural Science Foundation, grant number 22ZR147750, Innovative clinical research project of Changzheng Hospital, grant number 2020 YLCYJ-Y 02, Characteristic medical service project for the Army of Changzheng Hospital, grant number 2020 CZWJFW 12, National Natural Science Foundation of China, grant number 82072051 and National Natural Science Foundation of China, grant number 81771964.